VX-993 was generally safe and well tolerated at all doses studied in the trial. The overall incidence of adverse events on VX-993 was similar to placebo. The majority of the AEs were mild or moderate ...

The acquisition of Adams marks Vertex’s seventh acquisition under Wind Point ownership Jeff Christmann serves as CEO of Adams The Vertex Companies, a portfolio company of Wind Point Partners, has ...

The pharmaceutical company experienced multiple setbacks in its pain program, according to Stifel’s research note. Following an End-of-Phase 2 meeting with the FDA, Vertex will no longer pursue a ...

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) stock is falling on Tuesday after the company’s pain data overshadowed strong second-quarter earnings. See real-time price for VRTX stock here. On Monday, the ...

Investing.com - H.C. Wainwright lowered its price target on Vertex Pharmaceuticals (NASDAQ: VRTX) to $478 from $550 while maintaining a Buy rating following setbacks in the company’s pain program.

A Vertex Pharmaceuticals drug viewed as a successor to a non-opioid pill that won a landmark FDA approval earlier this year has failed a mid-stage clinical trial, dealing a setback to the company’s ...